|
Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ROS study. |
|
|
Consulting or Advisory Role - Amgen; Merck Serono; Roche; Sanofi; SERVIER |
Speakers' Bureau - Amgen; Merck Serono; Roche; Sanofi; SERVIER |
Travel, Accommodations, Expenses - Merck Serono; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb/Pfizer; Celgene; Daiichi Sankyo; Incyte; LEO Pharma; Lilly; MSD Oncology; Roche; Sanofi |
|
Research Funding - LEO Pharma; Sanofi |
Patents, Royalties, Other Intellectual Property - Risk assessment model in venous thromboembolism in cancer patients |
Travel, Accommodations, Expenses - Amgen; Celgene; Merck Serono; Roche |
|
|
Consulting or Advisory Role - Sanofi |
|
|
Other Relationship - IPSEN |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Ferrer; Lilly; Merck; MSD; Roche; Sanofi; SERVIER |
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; MSD; Roche; SERVIER |
Travel, Accommodations, Expenses - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Ferrer; Lilly; Merck; MSD; Roche; Sanofi; SERVIER |
|
|
Employment - Bausch and Lomb |
Honoraria - Bausch and Lomb; Sanofi |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Pfizer; Roche/Genentech |
|
Research Funding - LEO Pharma (Inst) |
Travel, Accommodations, Expenses - Ipsen; Novartis; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |